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Self-Reported Smoking, Urine Cotinine, and Risk of Cardiovascular
Disease: Findings From the PREVEND (Prevention of Renal and
Vascular End-Stage Disease) Prospective Cohort Study
Setor K. Kunutsor, MD, PhD; Julia M. Spee, BSc; Lyanne M. Kieneker, MSc; Ron T. Gansevoort, MD, PhD; Robin P. F. Dullaart, MD, PhD;
Albert-Jan Voerman, PhD; Daan J. Touw, PhD; Stephan J. L. Bakker, MD, PhD
Background-—We aimed to compare the associations of smoking exposure as assessed by self-reports and urine cotinine with
cardiovascular disease (CVD) risk and determine the potential utility of cotinine for CVD risk prediction.
Methods and Results-—Smoking status by self-reports and urine cotinine were assessed at baseline in 4737 participants (mean age,
53 years) of the PREVEND (Prevention of Renal and Vascular End-Stage Disease) prospective study. Participants were classiﬁed as
never, former, light current (≤10 cigarettes/day), and heavy current smokers (>10 cigarettes/day) according to self-reports and
analogous cutoffs for urine cotinine. During amedian follow-up of 8.5 years, 296 ﬁrst CVD events were recorded. Compared with self-
reported never smokers, the hazard ratios (95% conﬁdence interval) of CVD for former, light current, and heavy current smokers were
0.86 (0.64–1.17), 1.28 (0.83–1.97), and 1.80 (1.27–2.57) in multivariate analysis. Compared with urine cotinine–assessed never
smokers, the corresponding hazard ratios of CVD for urine cotinine–assessed former, light current, and heavy current smokers were
1.70 (1.03–2.81), 1.62 (1.15–2.28), and 1.95 (1.39–2.73) respectively. The C-index change on adding urine cotinine–assessed
smoking status to a standard CVD risk prediction model (without self-reported smoking status) was 0.0098 (0.0031–0.0164;
P=0.004). The corresponding C-index change for self-reported smoking status was 0.0111 (0.0042–0.0179; P=0.002).
Conclusions-—Smoking status as assessed by self-reports and urine cotinine is associated with CVD risk; however, the nature of
the association of urine cotinine with CVD is consistent with a dose-response relationship. The ability of urine cotinine to improve
CVD risk assessment is similar to that of self-reported smoking status. ( J Am Heart Assoc. 2018;7:e008726. DOI: 10.1161/
JAHA.118.008726.)
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C ardiovascular disease (CVD) is still the leading cause ofglobal mortality; in 2015, there were an estimated
422.7 million CVD cases and 17.9 million deaths globally.1 It
has been estimated that by 2030, over 23.6 million people
will die from CVD.2 Major risk factors for CVD include a
history of diabetes mellitus, blood pressure, and blood lipids,
as well as smoking status.3 Cigarette smoking is highly
prevalent globally, and its effect on CVD as well as all-cause
mortality is well established.4–7 Indeed, the literature is a
mineﬁeld of studies that have shown smoking to be an
important cause of cardiovascular outcomes, which include
coronary heart disease (CHD) and stroke. A strong dose-
response relationship has been demonstrated between
cigarette smoking and CVD.7,8 In fact, the strong epidemio-
logical link suggests a causal link between smoking and CVD.
Notably, data on smoking exposure in these studies have
mostly been dependent on self-reports. There is, however, a
challenge in the use of self-reported smoking exposure; the
assessment of smoking status by questionnaires may lead to
inaccurate measures of smoking exposure due to smoking
denial or difﬁculty in recalling the quantity and duration of
smoking.9,10 This misclassiﬁcation potentially leads to the
underestimation of the biological effects of smoking
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exposure. Cotinine is the major metabolite of nicotine and has
a long biological half-life of between 19 and 40 hours in the
body compared with nicotine, which has a short half-life of
about 30 minutes to 2 hours.11 Cotinine is considered a
highly sensitive and speciﬁc biomarker of cigarette smoking
and is considered to be the gold standard measure of smoking
exposure.11,12 Cotinine concentrations can be accurately
determined in serum or urine.13
A limited number of studies have evaluated the associations
between cotinine-assessed smoke exposure and the risk of
cardiovascular outcomes and reported increased levels of
blood cotinine to be associated with an increased risk of these
outcomes.14,15 However, there are uncertainties remaining
regarding the nature, shape, and magnitude of the association
between cotinine-assessed cigarette smoking exposure and
the risk of CVD because these previous reports were either
cross sectional in design, were based on subclinical cardiovas-
cular outcomes, or were insufﬁciently powerful to address
these aspects of the association.14,15Whether a dose-response
relationship exists for the potential association is also not
known. Furthermore, whether the assessment of cigarette
smoking on the basis of self-reports underestimates the risk
between smoking status and CVD as a result of misclassiﬁca-
tion has not been previously investigated.
In this context, we aimed to compare in detail the
associations of smoking exposure as assessed by self-reports
and urine cotinine with the risk of CVD. We also aimed to
determine the potential utility of urine cotinine for CVD risk
prediction.
Materials and Methods
The data, analytic methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure. We conducted
this study in accordance with STROBE (Strengthening the
Reporting of Observational Studies in Epidemiology) guideli-
nes for reporting observational studies in epidemiology
(Table S1).16
Study Design and Population
The participants in this study were part of the PREVEND
(Prevention of Renal and Vascular End-Stage Disease) study, a
general population–based prospective cohort study designed
to investigate the natural course of urinary albumin excretion
and its relationship to renal disease and CVD. The study
design details and recruitment have been described in
previous reports.17,18 Participants in PREVEND consisted of
a representative sample of inhabitants living in the city of
Groningen in the Netherlands. The present cohort comprised
6894 individuals aged 32 to 80 years, who were invited for
the second screening phase of the PREVEND study. Baseline
examinations and measurements were performed between
2001 and 2003. In the present analysis, we used data of
participants who had not experienced CVD, renal disease, or
malignancy at baseline. This left a cohort of 4737 participants
with nonmissing information on urine cotinine, smoking
exposure on the basis of self-reports, relevant covariates,
and incident cardiovascular outcomes. The local ethics
committee of the University Medical Center Groningen
approved the PREVEND study, which was conducted in
accordance with the Declaration of Helsinki. All participants
provided written informed consent.
Assessment of Exposures and Risk Factors
Study participants completed 2 outpatient visits, during which
baseline data on sociodemographics, anthropometric mea-
surements, medical history, and use of medication were
assessed or collected. Further information on medication use
was complemented with data from all community pharmacies
in the city of Groningen, which covers complete information
on drug use in 95% of PREVEND participants.19 After an
overnight fast and 15 minutes of rest, plasma and serum
venous samples were taken from participants on which
biomarker analyses were performed. Samples of 24-hour
urine collections were collected and stored at 80°C until
assessment of cotinine. Cotinine concentrations were mea-
sured using the Immulite 2500 assay (Siemens, Los Angeles,
CA) with the intra- and interassay coefﬁcient of variation
ranging from 2.2% to 5.7%. Smoking status was obtained by
self-reports. Participants provided details on their smoking
Clinical Perspective
What Is New?
• In a population-based prospective study of white men and
women without a history of cardiovascular disease at
baseline, smoking status as assessed by self-reports and
urine cotinine is associated with risk of cardiovascular
disease.
• Compared with self-reports, the magnitude of the associa-
tion using urine cotinine appears stronger and is consistent
with a dose-response relationship.
• The ability of urine cotinine to improve cardiovascular
disease risk assessment is similar to that provided by self-
reported smoking status.
What Are the Clinical Implications?
• Urine cotinine may be equal to or better than self-reported
smoking for the assessment of smoking exposure.
• In approaches that integrate smoking exposure in the
primary prevention of cardiovascular disease, urine cotinine
may serve as a reliable marker in instances where self-
reports are unreliable or cannot be ascertained.
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habits, which included number of cigarettes smoked and
duration of smoking. Smoking status was categorized as
never smokers, former smokers, light current smokers, and
heavy current smokers. Former smokers were those who
were nonsmokers at the time of study inclusion but had ever
smoked in their life, and current smokers were those who
reported smoking at the time of inclusion. Light current
smokers were current smokers who reported smoking ≤10
cigarettes per day, and heavy current smokers were current
smokers who reported smoking >10 cigarettes per day. Blood
pressure values were recorded as the mean of the last 2
readings of both visits.
Total cholesterol, high-density lipoprotein cholesterol, high-
sensitivity C-reactive protein (hsCRP), triglycerides, serum
creatinine, and serum cystatin C were measured using
standard laboratory protocols, which have been described in
previous reports.20–24 Plasma glucose was measured by dry
chemistry (Eastman Kodak, Rochester, NY). Estimated
glomerular ﬁltration rate was calculated using the Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI) com-
bined creatinine–cystatin C equation.25 Hypertension was
deﬁned as systolic blood pressure of ≥140 mm Hg, a diastolic
blood pressure of ≥90 mm Hg, and/or the use of antihyper-
tensive medication, in accordance with recommendations
from the Seventh Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood
Pressure.26
Ascertainment of Outcomes
The primary outcome for this study was ﬁrst-onset composite
CVD, with incident CHD and stroke as secondary outcomes.
Dates and causes of death were ascertained by record linkage
with the Dutch Central Bureau of Statistics. Information on
hospitalization for cardiovascular morbidity was retrieved
from Prismant, the Dutch national registry of hospital
discharge diagnoses.27 All outcome data were coded accord-
ing to the International Classiﬁcation of Diseases, Ninth
Revision (ICD-9) until January 1, 2009. After that date, the
data were coded according to ICD, Tenth Revision (ICD-10)
codes. First-onset CVD was deﬁned as the combined end
point of acute and subacute ischemic heart disease, acute
myocardial infarction, coronary artery bypass grafting or
percutaneous transluminal coronary angioplasty, subarach-
noid hemorrhage, intracerebral hemorrhage, other intracranial
hemorrhage, occlusion or stenosis of the precerebral or
cerebral arteries, and other vascular interventions such as
percutaneous transluminal angioplasty or bypass grafting of
peripheral vessels and aorta. CHD events were deﬁned as
fatal or nonfatal ischemic heart disease, fatal or nonfatal
myocardial infarction, coronary artery bypass graft, and
percutaneous transluminal coronary angioplasty. Stroke
events were deﬁned as subarachnoid hemorrhage, intracere-
bral hemorrhage, other and unspeciﬁed intracranial hemor-
rhage, occlusion and stenosis of precerebral or cerebral
arteries, and carotid obstruction.
Statistical Analyses
Skewed variables (eg, hsCRP, creatinine, and urinary albumin
excretion) were natural logarithm (loge) transformed to
achieve approximately normal distributions. We summarized
baseline characteristics of participants using descriptive
statistics. Normally distributed variables are presented as
means (standard deviation) and variables with a skewed
distribution are given as median (interquartile range). Contin-
uous and categorical variables were compared between
groups by ANOVA and chi-square testing, respectively. q
coefﬁcient was estimated to measure the degree of associ-
ation between self-reported smoking status and urine
cotinine–measured smoking status. To assess the measure
of agreement of the classiﬁcation of smoking exposure on the
basis of self-report and urine cotinine, we calculated Cohen’s
kappa (j). A j <0.21 is considered poor, a j between 0.21
and 0.40 is considered weak; a j between 0.41 and 0.60 is
considered moderate; a j between 0.61 and 0.80 is
considered strong; and a j >0.80 is considered very strong.28
Time-to-event Cox proportional hazards models were used to
assess the associations of smoking exposure as assessed by
self-report and cotinine concentrations with risk of CVD, after
conﬁrmation of no major departure from the proportionality-
of-hazards assumptions.29 We categorized cotinine-assessed
smoking exposure as never smokers, former smokers, light
current smokers, and heavy current smokers on the basis of
cutoffs for urine cotinine reported in the literature. The cutoffs
for urine cotinine were <100 ng/mL, 100 to 500 ng/mL, and
>500 ng/mL for the categories of never smokers, former
smokers, and current smokers, respectively, as employed in
several previous reports.30–33 Current smokers were then
subdivided into light and heavy current smokers on the basis
of the median cotinine level in current smokers, as reported in
a previous study.31 We plotted cumulative Kaplan-Meier
curves for CVD during follow-up according to categories of
smoking status as assessed by self-report and urine cotinine.
To assess the independence of the association between
smoking exposure and CVD risk, hazard ratios were calculated
with progressive adjustment for age and sex, other estab-
lished CVD risk factors (history of diabetes mellitus, systolic
blood pressure, total cholesterol, and high-density lipoprotein
cholesterol), other potential confounders (body mass index,
alcohol consumption, fasting glucose, and estimated glomeru-
lar ﬁltration rate), and hsCRP. Given that assuming a linear
relationship between a continuous variable (urine cotinine)
and an outcome (CVD) can yield misleading analyses, we
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employed a multivariate fractional polynomials model,34
which allows for ﬂexible modeling of the relationship
between urine cotinine and risk of CVD. We used interac-
tion tests to assess statistical evidence of effect modiﬁca-
tion by relevant clinical characteristics. To minimize bias
due to reverse causation, we performed sensitivity analyses
that excluded the ﬁrst 2 years of follow-up, participants
with a history of diabetes mellitus at baseline, or partici-
pants on regular statin medication.
To assess whether adding information on urine cotinine
assessed smoking exposure to conventional cardiovascular
risk factors35 is associated with an improvement in the
prediction of CVD risk, we calculated measures of discrim-
ination for censored time-to-event data (Harrell’s C-index36)
and reclassiﬁcation. To investigate the change in C-index, we
added smoking status to a model on the basis of traditional
risk factors included in the Framingham CVD Risk Score (ie,
age, sex, systolic blood pressure, total cholesterol, and high-
density lipoprotein cholesterol).37 Second, we evaluated
whether urine cotinine–assessed smoking exposure helps to
correctly classify participants into categories of predicted
CVD risk. Using the cardiovascular risk categories of low
(<5%), intermediate (5 to <7.5%), and high (≥7.5%) risk,38
reclassiﬁcation was assessed using the categorical net
reclassiﬁcation improvement.39 Reclassiﬁcation analysis was
based on the 9 years of follow time for this study. Finally, we
calculated the integrated discrimination improvement (IDI),
which integrates the net reclassiﬁcation improvement over all
possible cutoffs and is equivalent to the difference in
discrimination slopes.39 Risk prediction analysis was
restricted to participants without a known history of diabetes
mellitus or CVD at baseline. All statistical analyses were
conducted using Stata version 14 (Stata Corp, College
Station, TX).
Table 1. Baseline Participant Characteristics Overall and According to Self-Reported Smoking Status
Overall (N=4737)
Mean (SD)
or Median
(IQR) or n (%)
Never Smokers
(N=1458)
Mean (SD) Median
(IQR) or n (%)
Former Smokers
(N=1997)
Mean (SD) or Median
(IQR) or n (%)
Light Current
Smokers (N=495)
Mean (SD) or
Median (IQR) or n (%)
Heavy Current
Smokers (N=787)
Mean (SD) or
Median (IQR) or n (%)
P Value for
ANOVA
Urine cotinine (ng/mL)* 370 (721) 11 (109) 47 (256) 805 (681) 1580 (753) <0.001
Questionnaire
Male 2156 (45.5) 578 (39.6) 992 (49.7) 214 (43.2) 372 (47.3) <0.001
Age at survey, y 53 (12) 52 (12) 55 (12) 52 (11) 50 (10) <0.001
History of diabetes mellitus 236 (5.0) 69 (4.7) 107 (5.4) 28 (5.7) 32 (4.1) 0.447
Alcohol consumers 3570 (75.4) 1007 (69.1) 1577 (79.0) 391 (79.0) 595 (75.6) <0.001
Regular use of antihypertensive
medication
742 (16.6) 197 (14.5) 393 (20.8) 68 (14.5) 84 (11.2) <0.001
Regular use of lipid-lowering
medication
126 (3.2) 37 (3.2) 60 (3.6) 14 (3.4) 15 (2.3) 0.498
Physical measurements
BMI, kg/m2 26.5 (4.3) 26.5 (4.4) 27.1 (4.2) 25.6 (4.2) 25.8 (4.1) <0.001
SBP, mm Hg 125 (19) 125 (19) 127 (19) 122 (17) 123 (18) <0.001
DBP, mm Hg 73 (9) 72 (9) 74 (9) 72 (9) 73 (9) <0.001
Lipid markers
Total cholesterol, mmol/L 5.47 (1.05) 5.34 (1.04) 5.51 (1.03) 5.42 (1.03) 5.63 (1.09) <0.001
HDL-C, mmol/L 1.28 (0.31) 1.29 (0.29) 1.29 (0.32) 1.28 (0.33) 1.21 (0.31) <0.001
Metabolic, inflammatory, and renal function markers
hsCRP, mg/L 1.30 (0.60–2.89) 1.05 (0.50–2.49) 1.35 (0.65–2.87) 1.21 (0.53–2.91) 1.81 (0.77–3.78) <0.001
Fasting plasma glucose, mmol/L 4.98 (1.08) 4.94 (1.10) 5.05 (1.10) 4.92 (0.96) 4.93 (1.07) 0.002
Creatinine, lmol/L 71 (62–80) 70 (62–79) 72 (64–82) 69 (62–78) 67 (60–76) <0.001
Cystatine C, mg/dL 0.90 (0.20) 0.87 (0.19) 0.91 (0.22) 0.92 (0.21) 0.92 (0.16) <0.001
eGFR, mL/min per 1.73 m2 92.4 (16.8) 94.1 (16.9) 90.7 (17.3) 92.3 (17.0) 93.8 (14.6) <0.001
Continuous variables are reported as meanSD or median (interquartile range) and categorical variables are reported as n (%). BMI indicates body mass index; DBP, diastolic blood
pressure; eGFR, estimated glomerular ﬁltration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration combined creatinine–cystatin C equation); HDL-C, high-
density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; IQR, interquartile range; SBP, systolic blood pressure; SD, standard deviation.
*Majority of participants had urine cotinine concentrations below the assay’s detection limit.
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Results
Baseline Characteristics
Baseline characteristics of all 4737 participants overall and
according to their self-reported smoking status are reported
in Table 1. The mean (standard deviation) age of participants
at baseline was 53 (12) years, and 45.5% were men. The mean
(standard deviation) of urine cotinine was 370 (721) ng/mL.
Former smokers were older, heavier, and more likely to have
preexisting disease such as diabetes mellitus and hyperten-
sion compared with other categories. Heavy current smokers
had higher levels of total cholesterol and hsCRP and lower
levels of high-density lipoprotein cholesterol compared with
other categories. There was a strong correlation between self-
reported smoking status and urine cotinine–measured smok-
ing status (q=0.76, P<0.001). However, the classiﬁcation of
self-report corresponded weakly with that of urine cotinine on
the basis of a Cohen’s j of 0.24 (interrater agreement of
45%). Table 2 shows a cross tabulation of self-reported
smoking status and urine cotinine–measured smoking status.
Of the 1458 self-reported never smokers, 8 (0.5%) had urine
cotinine concentrations consistent with active smoking; and
of the 1997 self-reported former smokers, 53 (2.7%) had urine
cotinine concentrations consistent with active smoking.
Hence, the misclassiﬁcation rate of active smokers (the
number of misclassiﬁed active smokers divided by the number
of self-reported active smokers40) was 4.8%. Furthermore, of
the 3407 never smokers as assessed by urine cotinine
concentrations, a majority (1887, 55.4%) were classiﬁed as
former smokers by self-reports.
Smoking Exposures and Risk of Incident CVD
During a median follow-up of 8.5 (interquartile range, 7.8–8.9)
years (37 392 person-years at risk), 296 incident CVD events
(annual rate 7.92/1000 person-years at risk; 95% conﬁdence
interval [CI], 7.06–8.87) were recorded. Cumulative hazard
curves showed increased risks of CVD among heavy current
smokers (as assessed by self-reports and urine cotinine)
compared with other categories of smoking exposure (P value
for log-rank test <0.05 for all; Figure 1). Table 3 shows the
associations of smoking exposure categories assessed by
self-reports and urine cotinine with the risk of CVD. Compared
with self-reported never smokers, the hazard ratio (95% CI) of
CVD for heavy current smokers was 1.93 (1.37–2.73) in the
analysis adjusted for established cardiovascular risk factors.
The association remained consistent on additional adjustment
for body mass index, alcohol consumption, glucose, and
estimated glomerular ﬁltration rate 1.96 (1.39–2.78). The
association was minimally attenuated by further adjustment
for loge hsCRP 1.80 (1.27–2.57). The associations of self-
reported former and light current smoking exposures with
CVD were not signiﬁcant. Fitting of a fractional polynomial
model suggested a linear dose-response relationship between
urine cotinine and CVD risk (Figure 2). Compared with urine
cotinine–assessed never smokers in analysis adjusted for
established cardiovascular risk factors, the hazard ratios (95%
CI) of CVD for the following urine cotinine assessed smoking
groups: former smokers, light current smokers, and heavy
current smokers were 1.65 (1.00–2.72), 1.68 (1.20–2.36),
and 2.04 (1.47–2.83), respectively. The hazard ratios were
1.70 (1.03–2.81), 1.62 (1.15–2.28), and 1.95, (1.39–2.73),
respectively, after further adjustment for other potential
confounders and loge hsCRP. In subsidiary analyses that
modeled urine cotinine as a continuous variable (per
1000 ng/mL), signiﬁcant positive associations were observed
in all models (Table 3). In separate analyses for other
cardiovascular outcomes, the associations of both exposures
were generally similar for CHD and stroke; except for less
robust associations of cotinine-assessed former smoking with
risk of CHD and stroke (Tables 4 and 5). In sensitivity
analyses, the hazard ratios remained similar on exclusion of
the ﬁrst 2 years of follow-up, people with diabetes mellitus at
baseline, or people on cholesterol-lowering medication
(Tables 6–8). In further sensitivity analyses, we assessed
the associations of urinary cotinine multiplied by urinary
volume and urinary cotinine/urine creatinine ratio with the
risk of CVD. In multivariate analyses that compared the top to
Table 2. Cross-Tabulation of Participants by Self-Reported Smoking Status and Urine Cotinine Measured Smoking Status
Self-Reported Smoking Status
Urine Cotinine–Assessed Smoking Status
TotalNever Smokers Former Smokers Light Current Smokers Heavy Current Smokers
Never smokers 1441 (98.8) 9 (0.6) 4 (0.3) 4 (0.3) 1458 (100.0)
Former smokers 1887 (94.5) 57 (2.9) 31 (1.6) 22 (1.1) 1997 (100.0)
Light current smokers 66 (13.3) 135 (27.3) 202 (40.8) 92 (18.6) 495 (100.0)
Heavy current smokers 13 (1.7) 26 (3.3) 315 (40.0) 433 (55.0) 787 (100.0)
Total 3407 (71.9) 227 (4.8) 552 (11.7) 551 (11.6) 4737 (100.0)
Data are n (%).
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the bottom tertiles of urinary cotinine*urinary volume and
urinary cotinine/urine creatinine ratio, there was an increased
risk of CVD (Tables 9 and 10). The associations of self-
reported and urine cotinine–assessed smoking status with
incident CVD were not signiﬁcantly modiﬁed by several
clinically relevant characteristics such as age and sex, except
for evidence of effect modiﬁcation by total cholesterol on the
association between self-reported smoking and CVD risk (P
for interaction=0.044). A strong association was observed in
those with total cholesterol levels ≥5.41 mmol/L compared
to a modest association in participants with cholesterol levels
<5.41 mmol/L (Figures 3 and 4).
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Figure 1. Cumulative Kaplan-Meier curves for cardiovascular disease during follow-up according to smoking exposure categories as assessed
by self-reports and urine cotinine. CVD indicates cardiovascular disease.
Table 3. Prospective Associations of Smoking Exposure With Development of Cardiovascular Disease
Smoking Exposure Events/Total
Model 1 Model 2 Model 3 Model 4
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Self-reported smoking
Never smokers 69/1458 ref ref ref ref
Former smokers 130/1997 0.89 (0.66–1.19) 0.425 0.87 (0.64–1.17) 0.359 0.87 (0.64–1.18) 0.383 0.86 (0.64–1.17) 0.337
Light current
smokers
31/495 1.27 (0.83–1.94) 0.274 1.31 (0.85–2.00) 0.218 1.34 (0.87–2.06) 0.180 1.28 (0.83–1.97) 0.259
Heavy current
smokers
66/787 2.10 (1.49–2.96) <0.001 1.93 (1.37–2.73) <0.001 1.96 (1.39–2.78) <0.001 1.80 (1.27–2.57) 0.001
Urine cotinine
Per 1000 ng/mL 296/4737 1.47 (1.29–1.68) <0.001 1.44 (1.26–1.65) <0.001 1.46 (1.27–1.67) <0.001 1.40 (1.22–1.61) <0.001
Never smokers 190/3407 ref ref ref ref
Former smokers 17/227 1.70 (1.04–2.80) 0.036 1.65 (1.00–2.72) 0.050 1.73 (1.05–2.86) 0.032 1.70 (1.03–2.81) 0.038
Light current
smokers
41/552 1.67 (1.19–2.35) 0.003 1.68 (1.20–2.36) 0.003 1.69 (1.20–2.38) 0.003 1.62 (1.15–2.28) 0.006
Heavy current
smokers
48/551 2.12 (1.54–2.93) <0.001 2.04 (1.47–2.83) <0.001 2.12 (1.52–2.96) <0.001 1.95 (1.39–2.73) <0.001
Model 1: Age and sex. Model 2: Model 1 plus history of diabetes mellitus, systolic blood pressure, total cholesterol, and high-density lipoprotein cholesterol. Model 3: Model 2 plus body
mass index, alcohol consumption, glucose, and estimated glomerular ﬁltration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration combined creatinine–
cystatin C equation). Model 4: Model 3 plus loge high-sensitivity C-reactive protein. CI indicates conﬁdence interval; HR, hazard ratio.
DOI: 10.1161/JAHA.118.008726 Journal of the American Heart Association 6
Self-Reported Smoking, Cotinine, and CVD Kunutsor et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on M
ay 15, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
Smoking Exposure and CVD Risk Prediction
A CVD risk prediction model comprising traditional risk
factors (excluding self-reported smoking) yielded a C-index of
0.8002 (95% CI, 0.7799–0.8205). On addition of information
on urine cotinine concentration–assessed smoking status to
this prognostic model, the C-index was 0.8100 (0.7905–
0.8294), representing a small signiﬁcant increase of 0.0098
(0.0031–0.0164; P=0.004). There was no improvement in the
classiﬁcation of participants into predicted CVD risk cate-
gories (net reclassiﬁcation improvement, 0.28%, 4.50 to
5.06%; P=0.908), whereas there was signiﬁcant improvement
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Figure 2. Hazard ratios for incident cardiovascular disease, by baseline concentrations of urine cotinine using multivariate fractional
polynomial models. A, Hazard ratios were adjusted for age and sex; B, adjustment in A plus history of diabetes mellitus, systolic blood pressure,
total cholesterol, and high-density lipoprotein cholesterol. A fractional polynomial was used to model the relationship between urine cotinine as
a continuous risk factor and cardiovascular disease. The shaded regions denote the 95% conﬁdence interval for the fractional polynomial model.
Table 4. Prospective Associations of Smoking Exposure With Development of Coronary Heart Disease
Smoking Exposure Events/Total
Model 1 Model 2 Model 3 Model 4
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Self-reported smoking
Never smokers 46/1458 ref ref ref ref
Former smokers 98/1997 1.00 (0.70–1.43) 0.988 0.97 (0.67–1.39) 0.863 0.97 (0.68–1.40) 0.879 0.96 (0.67–1.39) 0.840
Light current
smokers
23/495 1.37 (0.83–2.26) 0.223 1.37 (0.83–2.27) 0.219 1.40 (0.85–2.33) 0.189 1.36 (0.82–2.27) 0.231
Heavy current
smokers
45/787 1.98 (1.30–2.99) 0.001 1.76 (1.16–2.68) 0.008 1.79 (1.17–2.73) 0.007 1.70 (1.11–2.61) 0.016
Urine cotinine
Per 1000 ng/mL 212/4737 1.46 (1.25–1.71) <0.001 1.41 (1.20–1.65) <0.001 1.42 (1.21–1.66) <0.001 1.39 (1.18–1.64) <0.001
Never smokers 137/3407 ref ref ref ref
Former smokers 10/227 1.33 (0.70–2.54) 0.381 1.24 (0.65–2.37) 0.518 1.31 (0.68–2.50) 0.418 1.30 (0.68–2.48) 0.433
Light current
smokers
29/552 1.56 (1.05–2.34) 0.029 1.57 (1.05–2.35) 0.028 1.58 (1.05–2.38) 0.027 1.54 (1.02–2.32) 0.038
Heavy current
smokers
36/551 2.09 (1.43–3.03) <0.001 1.90 (1.30–2.79) 0.001 1.98 (1.35–2.92) 0.001 1.90 (1.28–2.81) 0.001
Model 1: Age and sex. Model 2: Model 1 plus history of diabetes mellitus, systolic blood pressure, total cholesterol, and high-density lipoprotein cholesterol. Model 3: Model 2 plus body
mass index, alcohol consumption, glucose, and estimated glomerular ﬁltration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration combined creatinine–
cystatin C equation). Model 4: Model 3 plus loge high-sensitivity C-reactive protein. CI indicates conﬁdence interval; HR, hazard ratio.
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if reclassiﬁcation was assessed as continuous variable, with
an integrated discrimination improvement of 0.0101 (95% CI,
0.0042–0.0161; P=0.001).
To compare the predictive ability of urine cotinine assessed
smoking status with that of self-reported smoking status in
the same sample, information on self-reported smoking status
Table 6. Prospective Associations of Smoking Exposure With Development of Cardiovascular Disease on Exclusion of First
2 Years of Follow-Up
Smoking Exposure Events/Total
Model 1 Model 2 Model 3 Model 4
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Self-reported smoking
Never smokers 53/1409 ref ref ref ref
Former smokers 109/1942 0.98 (0.70–1.37) 0.908 0.96 (0.69–1.35) 0.836 0.98 (0.70–1.38) 0.917 0.97 (0.69–1.37) 0.870
Light current
smokers
21/472 1.13 (0.68–1.87) 0.646 1.15 (0.69–1.91) 0.591 1.18 (0.71–1.97) 0.528 1.13 (0.68–1.89) 0.633
Heavy current
smokers
50/753 2.14 (1.45–3.17) <0.001 1.99 (1.34–2.96) 0.001 2.02 (1.35–3.01) 0.001 1.88 (1.25–2.82) 0.002
Urine cotinine
Per 1000 ng/mL 233/4576 1.40 (1.20–1.64) <0.001 1.38 (1.17–1.62) <0.001 1.38 (1.17–1.62) <0.001 1.34 (1.13–1.58) <0.001
Never smokers 155/3305 ref ref ref ref
Former smokers 14/218 1.75 (1.01–3.02) 0.046 1.67 (0.96–2.91) 0.068 1.74 (1.00–3.03) 0.049 1.71 (0.99–2.98) 0.056
Light current
smokers
28/528 1.41 (0.94–2.12) 0.094 1.41 (0.94–2.12) 0.093 1.42 (0.95–2.14) 0.091 1.37 (0.91–2.06) 0.134
Heavy current
smokers
36/525 2.00 (1.38–2.89) <0.001 1.94 (1.33–2.82) 0.001 1.98 (1.35–2.90) <0.001 1.84 (1.25–2.71) 0.002
Model 1: Age and sex. Model 2: Model 1 plus history of diabetes mellitus, systolic blood pressure, total cholesterol, and high-density lipoprotein cholesterol. Model 3: Model 2 plus body
mass index, alcohol consumption, glucose, and estimated glomerular ﬁltration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration combined creatinine–
cystatin C equation). Model 4: Model 3 plus loge high-sensitivity C-reactive protein. CI indicates conﬁdence interval; HR, hazard ratio.
Table 5. Prospective Associations of Smoking Exposure With Development of Stroke
Smoking Exposure Events/Total
Model 1 Model 2 Model 3 Model 4
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Self-reported smoking
Never smokers 23/1458 ref ref ref ref
Former smokers 31/1997 0.68 (0.39–1.19) 0.178 0.68 (0.39–1.19) 0.172 0.71 (0.40–1.24) 0.227 0.68 (0.39–1.20) 0.184
Light current
smokers
7/495 0.94 (0.40–2.19) 0.878 1.00 (0.43–2.34) 0.995 1.09 (0.46–2.57) 0.851 1.02 (0.43–2.41) 0.965
Heavy current
smokers
22/787 2.39 (1.31–4.37) 0.005 2.33 (1.27–4.26) 0.006 2.49 (1.35–4.59) 0.003 2.15 (1.16–4.00) 0.015
Urine cotinine
Per 1000 ng/mL 83/4737 1.51 (1.17–1.96) 0.002 1.56 (1.20–2.03) 0.001 1.59 (1.22–2.07) 0.001 1.50 (1.14–1.96) 0.003
Never smokers 53/3407 ref ref ref ref
Former smokers 4/227 1.45 (0.52–4.02) 0.474 1.53 (0.55–4.24) 0.416 1.66 (0.60–4.61) 0.334 1.58 (0.57–4.41) 0.380
Light current
smokers
13/552 2.02 (1.09–3.72) 0.024 2.02 (1.09–3.72) 0.025 2.12 (1.14–3.93) 0.017 1.99 (1.07–3.70) 0.029
Heavy current
smokers
13/551 2.25 (1.21–4.18) 0.010 2.41 (1.29–4.52) 0.006 2.56 (1.36–4.83) 0.004 2.21 (1.16–4.20) 0.016
Model 1: Age and sex. Model 2: Model 1 plus history of diabetes mellitus, systolic blood pressure, total cholesterol, and high-density lipoprotein cholesterol. Model 3: Model 2 plus body
mass index, alcohol consumption, glucose, and estimated glomerular ﬁltration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration combined creatinine–
cystatin C equation). Model 4: Model 3 plus loge high-sensitivity C-reactive protein. CI indicates conﬁdence interval; HR, hazard ratio.
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was added to the model containing conventional risk factors.
There was a C-index change of 0.0111 (95% CI, 0.0042–
0.0179 P=0.002). After taking into account inappropriate
reclassiﬁcation, there was no signiﬁcant improvement in the
classiﬁcation of participants into the predicted CVD risk
categories (net reclassiﬁcation improvement, 1.86%, 2.92 to
Table 7. Prospective Associations of Smoking Exposure With Development of Cardiovascular Disease on Exclusion of Participants
With a History of Diabetes Mellitus at Baseline
Smoking Exposure Events/Total
Model 1 Model 2 Model 3 Model 4
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Self-reported smoking
Never smokers 60/1389 ref ref ref ref
Former smokers 114/1890 0.88 (0.64–1.22) 0.452 0.88 (0.64–1.22) 0.456 0.88 (0.63–1.21) 0.424 0.86 (0.62–1.20) 0.378
Light current
smokers
28/467 1.33 (0.85–2.08) 0.220 1.39 (0.88–2.19) 0.153 1.39 (0.88–2.18) 0.160 1.33 (0.84–2.10) 0.221
Heavy current
smokers
62/755 2.16 (1.51–3.10) <0.001 1.98 (1.37–2.84) <0.001 1.98 (1.37–2.85) <0.001 1.80 (1.24–2.61) 0.002
Urine cotinine
Per 1000 ng/mL 264/4501 1.50 (1.31–1.72) <0.001 1.47 (1.27–1.69) <0.001 1.47 (1.28–1.70) <0.001 1.41 (1.22–1.64) <0.001
Never smokers 165/3235 ref ref ref ref
Former smokers 16/218 1.82 (1.09–3.05) 0.022 1.82 (1.09–3.05) 0.023 1.87 (1.12–3.15) 0.017 1.84 (1.10–3.09) 0.021
Light current
smokers
38/521 1.75 (1.23–2.49) 0.002 1.73 (1.22–2.47) 0.002 1.73 (1.21–2.47) 0.003 1.65 (1.15–2.36) 0.006
Heavy current
smokers
45/527 2.26 (1.62–3.17) <0.001 2.19 (1.56–3.09) <0.001 2.24 (1.58–3.17) <0.001 2.03 (1.43–2.89) <0.001
Model 1: Age and sex. Model 2: Model 1 plus systolic blood pressure, total cholesterol, and high-density lipoprotein cholesterol. Model 3: Model 2 plus body mass index, alcohol
consumption, glucose, and estimated glomerular ﬁltration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration combined creatinine–cystatin C equation).
Model 4: Model 3 plus loge high-sensitivity C-reactive protein. CI indicates conﬁdence interval; HR, hazard ratio.
Table 8. Prospective Associations of Smoking Exposure With Development of Cardiovascular Disease on Exclusion of Participants
on Cholesterol-Lowering Medication
Smoking Exposure Events/Total
Model 1 Model 2 Model 3 Model 4
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Self-reported smoking
Never smokers 62/1421 ref ref ref ref
Former smokers 121/1937 0.91 (0.66–1.24) 0.542 0.90 (0.66–1.23) 0.513 0.91 (0.66–1.25) 0.549 0.90 (0.65–1.23) 0.498
Light current
smokers
28/481 1.27 (0.81–1.99) 0.291 1.33 (0.85–2.08) 0.219 1.35 (0.86–2.13) 0.189 1.29 (0.82–2.03) 0.272
Heavy current
smokers
64/772 2.22 (1.56–3.17) <0.001 2.06 (1.44–2.95) <0.001 2.10 (1.46–3.01) <0.001 1.92 (1.33–2.76) <0.001
Urine cotinine
Per 1000 ng/mL 275/4611 1.47 (1.29–1.69) <0.001 1.45 (1.26–1.66) <0.001 1.46 (1.27–1.68) <0.001 1.40 (1.21–1.62) <0.001
Never smokers 175/3313 ref ref ref ref
Former smokers 16/219 1.79 (1.07–2.99) 0.027 1.73 (1.03–2.91) 0.037 1.80 (1.07–3.03) 0.026 1.76 (1.05–2.96) 0.031
Light current
smokers
39/540 1.69 (1.19–2.40) 0.003 1.70 (1.20–2.41) 0.003 1.71 (1.20–2.43) 0.003 1.63 (1.14–2.32) 0.007
Heavy current
smokers
45/539 2.12 (1.52–2.96) <0.001 2.06 (1.47–2.90) <0.001 2.13 (1.51–3.00) <0.001 1.94 (1.37–2.75) <0.001
Model 1: Age and sex. Model 2: Model 1 plus history of diabetes mellitus, systolic blood pressure, total cholesterol, and high-density lipoprotein cholesterol. Model 3: Model 2 plus body
mass index, alcohol consumption, glucose, and estimated glomerular ﬁltration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration combined creatinine–
cystatin C equation). Model 4: Model 3 plus loge high-sensitivity C-reactive protein. CI indicates conﬁdence interval; HR, hazard ratio.
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6.64%; P=0.447), whereas there was signiﬁcant improvement
if reclassiﬁcation was assessed as a continuous variable, with
an integrated discrimination improvement of 0.0102 (0.0040–
0.0164; P=0.001).
Discussion
Summary of Main Findings
We have evaluated the associations of smoking exposure (as
assessed by self-reports and urine cotinine) with the risk of
CVD in a population-based prospective cohort study compris-
ing white men and women without a history of CVD at
baseline. By using cotinine-based measurements of smoking
exposure, 61 (1.8%) of 3455 self-reported never and former
smokers could be reclassiﬁed as active smokers (misclassi-
ﬁcation rate of 4.8%). More than half of urine cotinine–
assessed never smokers were classiﬁed as former smokers by
self-reports, which reﬂects evidence questioning the reliability
of cotinine in distinguishing between never smoking and
former smoking.31 In addition, we observed a strong corre-
lation between self-reported smoking and urine cotinine–
assessed smoking status. However, the kappa value sug-
gested weak agreement between self-report and urine
cotinine in smoking status classiﬁcation. Compared with
self-reported never smokers, self-reported heavy current
smokers had an increased risk of CVD, and this association
was independent of several established cardiovascular risk
factors and other potential confounders. However, the
associations of self-reported former and light current smoking
exposures with CVD were not signiﬁcant. On evaluation of the
association between smoking status as assessed by urine
cotinine and risk of CVD, former smokers, light current
smokers, and heavy current smokers were each indepen-
dently associated with an increased risk of CVD, and this was
consistent with a linear dose-response relationship. The
associations were similar in several sensitivity analyses. The
magnitudes of the associations were generally similar for the
speciﬁc end points of CHD and stroke, except for modest
associations of cotinine-assessed former smoking with risk of
CHD and stroke, which could be attributed to the low event
rate in that smoking exposure category. Though the associ-
ation between self-reported smoking and CVD risk was
signiﬁcantly modiﬁed by total cholesterol, the associations
remained generally consistent across several clinically rele-
vant subgroups such as age and sex for both exposures. The
stronger association between smoking status and CVD risk in
participants with high cholesterol levels (≥5.41 mmol/L) may
be consistent with established evidence that shows that
smoking is associated with a more atherogenic lipid proﬁle
(higher total cholesterol and triglyceride with lower high-
density lipoprotein cholesterol levels) and increases the risk
of CHD in people with high cholesterol levels and other risk
factors that increase the risk of CVD.41,42 Though there was
Table 10. Prospective Associations of Smoking Exposure (Urine Cotinine/Urine Creatinine Ratio) With Development of
Cardiovascular Disease
Smoking Exposure,
ng/mmol per L Events/Total
Model 1 Model 2 Model 3 Model 4
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Tertile 1 159/2785 ref ref ref ref
Tertile 2 16/320 0.96 (0.57–1.61) 0.880 0.97 (0.58–1.62) 0.907 0.96 (0.57–1.61) 0.871 0.93 (0.55–1.55) 0.771
Tertile 3 118/1552 1.72 (1.35–2.19) <0.001 1.67 (1.31–2.13) <0.001 1.72 (1.34–2.19) <0.001 1.63 (1.27–2.09) <0.001
Model 1: Age and sex. Model 2: Model 1 plus history of diabetes mellitus, systolic blood pressure, total cholesterol, and high-density lipoprotein cholesterol. Model 3: Model 2 plus body
mass index, alcohol consumption, glucose, and estimated glomerular ﬁltration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration combined creatinine–
cystatin C equation). Model 4: Model 3 plus loge high-sensitivity C-reactive protein. CI indicates conﬁdence interval; HR, hazard ratio.
Table 9. Prospective Associations of Smoking Exposure (Urine Cotinine Multiplied by Urinary Volume) With Development of
Cardiovascular Disease
Smoking
Exposure (ng) Events/Total
Model 1 Model 2 Model 3 Model 4
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Tertile 1 162/2837 ref ref ref ref
Tertile 2 16/318 1.02 (0.61–1.70) 0.945 1.00 (0.60–1.67) 0.998 0.99 (0.59–1.66) 0.969 0.96 (0.57–1.60) 0.866
Tertile 3 118/1577 1.68 (1.32–2.13) <0.001 1.63 (1.28–2.08) <0.001 1.68 (1.31–2.14) <0.001 1.59 (1.24–2.03) <0.001
Model 1: Age and sex. Model 2: Model 1 plus history of diabetes mellitus, systolic blood pressure, total cholesterol, and high-density lipoprotein cholesterol. Model 3: Model 2 plus body
mass index, alcohol consumption, glucose, and estimated glomerular ﬁltration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration combined creatinine–
cystatin C equation). Model 4: Model 3 plus loge high-sensitivity C-reactive protein. CI indicates conﬁdence interval; HR, hazard ratio.
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no signiﬁcant evidence of effect modiﬁcation by sex on the
associations, the associations were more extreme for men
compared with women, which may reﬂect evidence that the
attributable risk of CHD as a result of smoking is generally
lower in women than in men.43 However, evidence suggests
that smoking has a much larger relative detrimental impact on
CHD in women, although the detrimental effect of smoking on
CVD in women with respect to men has mostly been
conﬂicting in studies and may be related to factors such as
differences in smoking habits in populations and cessation
during follow-up.43 Given the absence of signiﬁcant evidence
of effect modiﬁcation by sex in our analyses and the low event
rate in women, the current results should be interpreted with
caution. Finally, addition of urine cotinine assessed smoking
status was not associated with a clinically meaningful
improvement in assessment of CVD risk, although the change
was statistically signiﬁcant, which could be attributed to the
relatively large sample size we employed. Additional analyses
in the same set of participants showed the improvement
provided by self-reported smoking exposure in prediction of
CVD risk was similar to that of urine cotinine, with no obvious
superiority of urine cotinine. Both exposures did not improve
the reclassiﬁcation of participants across clinical risk cate-
gories currently recommended to inform decisions about the
initiation of preventive treatment.38
Comparison With Previous Work
We are unable to directly compare the current ﬁndings with
previous work, as our search of the literature did not identify
any prospective study that has assessed and also compared
the associations of smoking exposure as assessed by self-
reports and urine cotinine with the risk of CVD. Of note,
Delgado and colleagues compared the association of plasma
cotinine and cigarette smoking in pack-years with cardiovas-
cular and all-cause mortality.15 Both exposures were signif-
icantly associated with both outcomes, and the magnitude of
the associations were higher for cotinine compared to pack-
Age at survey (years)
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History of diabetes
No
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Systolic blood pressure (mmHg)
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≥ 123
Total cholesterol (mmol/l)
< 5.41
≥ 5.41
HDL-cholesterol (mmol/l)
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< 94.07
≥ 94.07
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≥ 1.30
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3,787
126
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No of participants
41
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No. of CVD events
4.33 (1.71, 10.93)
1.45 (0.99, 2.12)
2.43 (1.55, 3.83)
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1.56 (0.85, 2.87)
2.25 (1.46, 3.47)
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0.92 (0.19, 4.48)
1.99 (1.38, 2.86)
1.50 (0.46, 4.91)
2.40 (1.40, 4.13)
1.67 (1.06, 2.61)
2.80 (1.54, 5.10)
1.63 (1.06, 2.52)
2.69 (1.31, 5.51)
1.72 (1.16, 2.55)
1.31 (0.71, 2.42)
2.33 (1.52, 3.58)
2.33 (1.50, 3.62)
1.50 (0.84, 2.66)
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p-value*
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Figure 3. Hazard ratios for self-reported smoking and cardiovascular disease risk by several participant-level characteristics. Hazard ratios
were adjusted for age, sex, history of diabetes mellitus, systolic blood pressure, total cholesterol, and high-density lipoprotein cholesterol; CI
indicates conﬁdence interval (bars); CVD, cardiovascular disease; HDL, high-density lipoprotein; HR, hazard ratio. *P value for interaction; cutoffs
used for fasting glucose, body mass index, systolic blood pressure, total cholesterol, HDL cholesterol, estimated glomerular ﬁltration rate (GFR),
and C-reactive protein are median values.
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years, ﬁndings that were consistent with the results of our
study. In a recent cross-sectional analysis, increased serum
cotinine levels were demonstrated to be associated with an
increased risk of subclinical myocardial injury.14 In our study,
we found a misclassiﬁcation rate of 5%. In comparison,
previous studies have reported misclassiﬁcation rates for
current smokers reporting themselves to be nonsmokers to
range from 0.8% to 15.3%.31,40 The strong correlation
observed between the 2 exposures is consistent with that
of a previous study.31 Consistent with our ﬁndings, a previous
study demonstrated serum cotinine, pack-years, or self-
reported smoking to signiﬁcantly improve mortality risk
prediction beyond traditional risk factors.15 The majority of
previously published studies have evaluated the associations
between cotinine-assessed passive smoke exposure and
the risk of CVD and have suggested dose-response
relationships.44–46
Possible Explanations for Findings
Our ﬁndings indicate that smoking exposure is associated
with an increased risk of CVD, which is consistent with
established evidence.4–7 Although there was no marked
superiority of urine cotinine over self-reported smoking status
in the associations, the stronger magnitude of the associa-
tions using cotinine-assessed smoking exposure and the
dose-dependent nature of the relationship suggest smoking
exposure using urine cotinine may be a more reliable indicator
than self-reported smoking. Indeed, it has been shown that
serum cotinine is better than self-report when quantifying the
risks with several outcomes.47 Cotinine measurements could
be a more reliable way of quantifying risks than are self-
reports for the following reasons: (1) potential for individuals
to underreport smoking exposure due to actual difﬁculty in
recalling or deliberate denial—misclassiﬁcation rates for
Age at survey (years)
< 50
≥ 50
Sex
Males
Females
Alcohol consumption
Non-alcohol consumers
Alcohol consumers
Use of statins
No
Yes
History of diabetes
No
Yes
Fasting glucose (mmol/l)
< 4.8
≥ 4.8
Body mass index (kg/m2)
< 24.97
≥ 24.97
Systolic blood pressure (mmHg)
< 123
≥ 123
Total cholesterol (mmol/l)
< 5.41
≥ 5.41
HDL-cholesterol (mmol/l)
< 1.25
≥ 1.25
Estimated GFR (ml/min/1.73 m2)
< 94.07
≥ 94.07
C-reactive protein (mg/l)
< 1.30
≥ 1.30
Subgroup
2,161
2,576
2,156
2,581
1167
3,570
3,787
126
4,501
236
2,400
2,337
2,370
2,367
2,417
2,320
2,373
2,364
2,377
2,360
2,369
2,368
2,370
2,367
No of participants
41
255
206
90
92
204
242
21
264
32
106
190
96
200
54
242
110
186
195
101
221
75
96
200
No. of CVD events
3.27 (1.62, 6.59)
1.47 (1.01, 2.14)
2.25 (1.55, 3.25)
1.48 (0.73, 3.00)
2.49 (1.44, 4.31)
1.87 (1.25, 2.80)
2.04 (1.42, 2.93)
2.45 (0.69, 8.68)
2.16 (1.54, 3.05)
1.12 (0.34, 3.71)
2.23 (1.36, 3.65)
1.93 (1.25, 2.97)
2.83 (1.74, 4.62)
1.70 (1.08, 2.67)
3.20 (1.69, 6.03)
1.66 (1.13, 2.44)
1.97 (1.13, 3.45)
2.18 (1.46, 3.25)
2.11 (1.44, 3.09)
2.04 (1.11, 3.78)
1.67 (1.10, 2.54)
2.82 (1.66, 4.79)
1.68 (0.86, 3.28)
2.09 (1.43, 3.06)
HR (95% CI)
.252
.291
.119
.928
.619
.978
.435
.376
.940
.718
.203
.119
P-value*
1.25 .5 .75 2.5 5 7.5 10 15.5
HR (95% CI) Urine cotinine assessed heavy compared with never smokers
Figure 4. Hazard ratios for urine cotinine assessed smoking and cardiovascular disease risk by several participant level characteristics.
Hazard ratios were adjusted for age, sex, history of diabetes mellitus, systolic blood pressure, total cholesterol, and high-density lipoprotein-
cholesterol; CI indicates conﬁdence interval (bars); CVD, cardiovascular disease; HDL, high-density lipoprotein; HR, hazard ratio. *P value for
interaction; cutoffs used for fasting glucose, body mass index, systolic blood pressure, total cholesterol, HDL cholesterol, estimated glomerular
ﬁltration rate (GFR), and C-reactive protein are median values.
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current smokers reporting themselves to be nonsmokers
have been reported to range from 0.8% to 15.3%40; and
(2) differences in cigarettes smoked and smoke inhalation,
which result in differences in smoking exposure among
individuals. Furthermore, it has been shown in a recent study
that quantiﬁcation of smoking exposure using cotinine
measurements led to signiﬁcant reclassiﬁcation compared
with self-report.31 Another study reported absence of a
correlation between self-reported cigarette smoking and
measured cotinine concentrations.15 The overall ﬁndings
suggest that it may be more reliable to assess smoking
exposure using objective measures such as cotinine assessed
in the saliva, hair, urine, or blood. Although cotinine, a major
metabolite of nicotine, has long been used as a marker of
smoking exposure, its use has some drawbacks. First, there is
variability in the amount of nicotine that is converted to
cotinine, which ranges between 55% and 92%.48 Second,
there is between-person variation in rates of metabolism and
excretion of cotinine. Third, cotinine cannot be used to reliably
distinguish between never smoking and former smoking.31
Fourth, cotinine may not be useful for distinguishing between
passive smoking and nonsmoking exposure groups.49 Fifth,
cotinine concentrations reﬂect smoking exposure of several
days and may not provide accurate estimates if there is a
break in smoking. Sixth, genetic factors that control nicotine
metabolism may inﬂuence cotinine concentrations.50 The
interrater reliability between self-report and urine cotinine in
smoking status classiﬁcation was weak, which may reﬂect
(1) some of the limitations of urine cotinine in distinguishing
between some smoking exposure categories, or (2) that urine
cotinine may indeed be a more reliable measure of smoking
status than is self-reported smoking. However, further
investigation is needed. Findings from our risk prediction
analysis showed that urine cotinine–assessed smoking expo-
sure augmented CVD risk prediction, which was comparable
to that of self-reported smoking status; this and the
observation of a graded association between urine cotinine
and CVD risk suggests that urine cotinine–assessed smok-
ing status is potentially suitable for population-level risk
assessment.
Strengths and Limitations
This is the ﬁrst comparative prospective assessment of the
associations of smoking exposure as measured by self-reports
and urine cotinine with the risk of composite CVD as well as
speciﬁc end points of CHD and stroke. We also compared the
potential utility of both exposures for CVD risk prediction.
Other strengths include the relatively large sample size, which
was also representative of the general population; the
extended follow-up enabling time-to-event analyses; exclusion
of individuals with a baseline history of CVD; and
measurements on a comprehensive panel of cardiovascular
risk markers that enabled adequate adjustment for potential
confounding. The cutoffs we employed to distinguish between
no smoking and active smoking were appropriate (have high
sensitivity and speciﬁcity values), conservative, and have been
used in several previous studies.30–33,49 To enhance the validity
of the ﬁndings, we restricted analyses to people with complete
information on exposures, risk factors, and outcomes. The
ﬁndings were robust to exclusion of the ﬁrst 2 years of follow-
up, participants with a history of diabetes mellitus at baseline,
or participants on regular statin medication. In addition to the
previously mentioned drawbacks to the use of cotinine as a
measure of smoking exposure, there were some other limita-
tions to our study. First, our analyses were based on a single
measure of cotinine, introducing the possibility of regression
dilution bias and underestimation of the association between
cotinine assessed smoking exposure and CVD risk. Second,
there was a potential for residual confounding due to other
unmeasured covariates and errors in measurements of risk
markers. Third, we classiﬁed urine cotinine–assessed light and
current smokers on the basis of the median urine cotinine
values of current smokers as reported in a previous study.31
Given the limited evidence on this approach, there is a
possibility of misclassiﬁcation. Finally, the ﬁndings may not
be generalizable to individuals of different ethnicities. Irrespec-
tive of the limitations, our overall ﬁndings suggest that urine
cotinine may be equal to or better than self-reported smoking
for the assessment of smoking exposure.
Conclusion
Smoking status as assessed by self-reports and urine cotinine
is associated with risk of CVD. However, the nature of the
association of urine cotinine with CVD is consistent with a
dose-response relationship. The ability of urine cotinine to
improve CVD risk assessment is similar to that provided by
self-reported smoking status.
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Table S1. STROBE 2007 Statement—Checklist of items that should be included in reports of cohort studies. 
 
Section/Topic 
Item 
# 
Recommendation Reported on page # 
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract Page 1 
(b) Provide in the abstract an informative and balanced summary of what was done and what was found Page 2 
Introduction  
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported Page 4 
Objectives 3 State specific objectives, including any prespecified hypotheses Page 4 
Methods  
Study design 4 Present key elements of study design early in the paper Study design and 
population 
 
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data 
collection 
Study design and 
population 
 
Participants 6 (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Study design and 
population 
 
(b) For matched studies, give matching criteria and number of exposed and unexposed Not applicable 
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Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if 
applicable 
Assessment of 
exposures and risk 
factors 
 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe 
comparability of assessment methods if there is more than one group 
Assessment of 
exposures and risk 
factors 
 
Bias 9 Describe any efforts to address potential sources of bias Statistical analyses 
 
Study size 10 Explain how the study size was arrived at Statistical analyses 
 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and 
why 
Statistical analyses 
 
Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding Statistical analyses 
 
(b) Describe any methods used to examine subgroups and interactions Statistical analyses 
 
(c) Explain how missing data were addressed Not applicable 
(d) If applicable, explain how loss to follow-up was addressed Not applicable 
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(e) Describe any sensitivity analyses Statistical analyses 
 
Results  
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed 
eligible, included in the study, completing follow-up, and analysed 
Study design and 
population 
 
  (b) Give reasons for non-participation at each stage Study design and 
population 
 
  (c) Consider use of a flow diagram Study design and 
population 
 
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential 
confounders 
Results; Table 1  
  (b) Indicate number of participants with missing data for each variable of interest  
  (c) Summarise follow-up time (eg, average and total amount) Results 
Outcome data 15* Report numbers of outcome events or summary measures over time Results 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence 
interval). Make clear which confounders were adjusted for and why they were included 
Results; Tables 2 and 
4 
  (b) Report category boundaries when continuous variables were categorized Results; Tables 2 and 
4 
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  (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period  
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses Results; Tables 5-10 
Discussion    
Key results 18 Summarise key results with reference to study objectives Discussion  
Limitations    
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from 
similar studies, and other relevant evidence 
Discussion 
Generalisability 21 Discuss the generalisability (external validity) of the study results Discussion 
Other information    
Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on 
which the present article is based 
Page 15-16 
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